Constituents in Kava extracts potentially involved in hepatotoxicity: A review

Chemical Research in Toxicology

Volumn 24, Issue 7, 2011, Pages 992-1002

  Olsen, Line R ^a   Grillo, Mark P ^b   Skonberg, Christian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA, 4ALPHA EPOXY 5BETA PIPERMETHYSTINE; ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALKALOID DERIVATIVE; ASPARTATE AMINOTRANSFERASE; AWAINE; BILIRUBIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D1; CYTOCHROME P450 2D6; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; DIHYDROMETHYSTICIN; FLAVOKAVAIN A; FLAVOKAVAIN B; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLYCOPROTEIN P; KAVA EXTRACT; LACTATE DEHYDROGENASE; LACTONE DERIVATIVE; METHYSTICIN; PIPERMETHYSTINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; YANGONIN;

ALCOHOL CONSUMPTION; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; COVALENT BOND; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIVER DISEASE; LIVER HYPERTROPHY; LIVER TOXICITY; METABOLITE; NONHUMAN; RASH; REVIEW; SKIN DISEASE; URINARY EXCRETION; URTICARIA;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG-INDUCED LIVER INJURY; EXANTHEMA; GLUTATHIONE; HUMANS; KAVA; LACTONES; PLANT ROOTS;

PIPER METHYSTICUM;

EID: 79960475169     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx100412m     Document Type: Review

References (85)

1. Norton, S. A. and Ruze, P. (1994) Kava dermopathy J. Am. Acad. Dermatol. 31, 89-97 (Pubitemid 24198170)
2. Lebot, V., Merlin, M., and Lindstrom, L. (1997) Kava the Pacific Drug, Yale University Press, New Haven, CT.
3. Singh, Y. N. and Singh, N. N. (2002) Therapeutic potential of kava in the treatment of anxiety disorders CNS Drugs 16, 731-743 (Pubitemid 35252722)
4. Gow, P. J., Connelly, N. J., Hill, R. L., Crowley, P., and Angus, P. W. (2003) Fatal fulminant hepatic failure induced by a natural therapy containing kava Med. J. Aust. 178, 442-443 (Pubitemid 36591919)
5. Denham, A., McIntyre, M., and Whitehouse, J. (2002) Kava: the unfolding story: report on a work-in-progress J. Altern. Complement. Med. 8, 237-263 (Pubitemid 34753400)
6. Russmann, S., Lauterburg, B. H., and Helbling, A. (2001) Kava hepatotoxicity Ann. Intern. Med. 135, 68-69
7. Thomsen, M., Vitetta, L., Schmidt, M., and Sali, A. (2004) Fatal fulminant hepatic failure induced by a natural therapy containing kava Med. J. Aust. 180, 198-199; author reply 199 (Pubitemid 38247959)
8. World Health Organization (2007) Assessments of the Risk of Hepatotoxicity with Kava Products, WHO Document Production Services, Geneva, Switzerland.
9. Teschke, R., Genthner, A., and Wolff, A. (2009) Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures J. Ethnopharmacol. 123, 378-384
10. Teschke, R. (2010) Kava hepatotoxicity. A clinical review Ann. Hepatol. 9, 251-265
11. Jamieson, D. D. and Duffield, P. H. (1990) Positive interaction of ethanol and kava resin in mice Clin. Exp. Pharmacol. Physiol. 17, 509-514 (Pubitemid 20242553)
12. Anke, J. and Ramzan, I. (2004)) Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.) J. Ethnopharmacol. 93, 153-160 (Pubitemid 38962400)
13. Schmidt, M. (2003) Is kava really hepatotoxic? An analysis of the known data on adverse effects of kava preparations on the liver. http://www.uni- muenster.de/Chemie.pb/forschen/Kava.html (accesed Nov 3, 2011).
14. Clough, A. R., Bailie, R. S., and Currie, B. (2003) Liver function test abnormalities in users of aqueous kava extracts J. Toxicol. Clin. Toxicol. 41, 821-829 (Pubitemid 37499010)
15. Teschke, R. (2010) Kava hepatotoxicity: pathogenetic aspects and prospective considerations Liver Int. 30, 1270-1279
16. Teschke, R. and Wollf, A. (2011) Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? Reg. Toxicol. Pharmacol. 59, 1-7
17. Teschke, R., Fuchs, J., Bahre, R., Genthner, A., and Wolff, A. (2010) Original article. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment J. Clin. Pharm. Ther. 35, 545-563
18. Centers of Disease Control and Prevention (2002) Hepatic toxicity possibly associated with kava-containing products: United States MMWR Morb. Mortal. Wkly. Rep. 51, 1065-1067
19. Clough, A. R., Jacups, S. P., Wang, Z., Burns, C. B., Bailie, R. S., Cairney, S. J., Collie, A., Guyula, T., McDonald, S. P., and Currie, B. J. (2003) Health effects of kava use in an eastern Arnhem Land Aboriginal community Intern. Med. J. 33, 336-340 (Pubitemid 37082791)
20. Brown, A. C., Onopa, J., Holck, P., Kaufusi, P., Kabasawa, D., Craig, W. J., Dragull, K., Levine, A. M., and Baker, J. D. (2007) Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii Clin. Toxicol. 45, 549-556 (Pubitemid 46763668)
21. Christl, S. U., Seifert, A., and Seeler, D. (2009) Toxic hepatitis after consumption of traditional kava preparation J. Travel Med. 16, 55-56
22. Pittler, M. H. and Ernst, E. (2003) Kava extract for treating anxiety Cochrane Database Syst. Rev. CD003383
23. Stevinson, C., Huntley, A., and Ernst, E. (2002) A systematic review of the safety of kava extract in the treatment of anxiety Drug Saf. 25, 251-261 (Pubitemid 34569359)
24. Bilia, A. R., Scalise, L., Bergonzi, M. C., and Vincieri, F. F. (2004) Analysis of kavalactones from Piper methysticum (kava-kava) J. Chromatogr., B 812, 203-214 (Pubitemid 39535412)
25. Dragull, K., Yoshida, W. Y., and Tang, C. S. (2003) Piperidine alkaloids from Piper methysticum Phytochemistry 63, 193-198 (Pubitemid 36560138)
26. Lebot, V. and Simeoni, P. (2004) Is the quality of kava (Piper methysticum Forst. f.) responsible for different geographical patterns Ethnobotany Res. Appl. 2, 19-28
27. Nelson, S. C. (2000) Awa Dieback in Hawaii Plant Disease 18, 1-8
28. Shulgin, A. T. (1973) The narcotic pepper: The chemistry and pharmacology of Piper methysticum and related species Bull. Narc. 25, 59-74
29. Jhoo, J.-W., Freeman, J. P., Heinze, T. M., Moody, J. D., Schnackenberg, L. K., Beger, R. D., Dragull, K., Tang, C.-S., and Ang, C. Y. W. (2006) In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum) J. Agric. Food Chem. 54, 3157-3162
30. Zhou, P., Gross, S., Liu, J. H., Yu, B. Y., Feng, L. L., Nolta, J., Sharma, V., Piwnica-Worms, D., and Qiu, S. X. (2010) Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B and MAPK signaling pathways FASEB J. 24, 4722-4732
31. Backleh, M., Ekici, P., Leupold, G., and Parlar, H. (2003) Quantitative elimination of Flavokavines A and B from Kava Kava (Piper methysticum G. Forst) by isoelectric focused adsorptive bubble separation Naturwissenschaften 90, 366-369 (Pubitemid 37129958)
32. Kuo, Y.-F., Su, Y.-Z., Tseng, Y.-H., Wang, S.-Y., Wang, H.-M., and Chueh, P. J. (2010) Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: Involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cells Free Radical Biol. Med. 49, 214-226
33. Kubatova, A., Miller, D. J., and Hawthorne, S. B. (2001) Comparison of subcritical water and organic solvents for extracting kava lactones from kava root J. Chromatogr., A 923, 187-194 (Pubitemid 32706394)
34. Whitton, P. A., Lau, A., Salisbury, A., Whitehouse, J., and Evans, C. S. (2003) Kava lactones and the kava-kava controversy Phytochemistry 64, 673-679 (Pubitemid 37176400)
35. Cote, C. S., Kor, C., Cohen, J., and Auclair, K. (2004) Composition and biological activity of traditional and commercial kava extracts Biochem. Biophys. Res. Commun. 322, 147-152 (Pubitemid 39093851)
36. Loew, D. and Franz, G. (2003) Quality aspects of traditional and industrial Kava-extracts Phytomedicine 10, 610-612 (Pubitemid 37092690)
37. Singh, Y. N. and Devkota, A. K. (2003) Aqueous kava extracts do not affect liver function tests in rats Planta Med. 69, 496-499 (Pubitemid 36870621)
38. Sorrentino, L., Capasso, A., and Schmidt, M. (2006) Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats Phytomedicine 13, 542-549 (Pubitemid 44224050)
39. Clayton, N. P., Yoshizawa, K., Kissling, G. E., Burka, L. T., Chan, P. C., and Nyska, A. (2007) Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract Exp. Toxicol. Pathol. 58, 223-236 (Pubitemid 44873076)
40. Westerink, W. M. A. and Schoonen, W. G. E. J. (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells Toxicol. in Vitro 21, 1581-1591 (Pubitemid 350103536)
41. Zou, L., Harkey, M. R., Henderson, G. L., and Dike, L. E. (2004) Kava does not display metabolic toxicity in a homogeneous cellular assay Planta Med. 70, 289-292 (Pubitemid 38594597)
42. Zou, L., Henderson, G. L., Harkey, M. R., Sakai, Y., and Li, A. (2004) Effects of kava (Kava-kava, Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes Phytomedicine 11, 285-294 (Pubitemid 38657457)
43. Clouatre, D. L. (2004) Kava kava: examining new reports of toxicity Toxicol. Lett. 150, 85-96 (Pubitemid 38447238)
44. Smith, D. A. and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579 (Pubitemid 44975120)
45. Fourches, D., Barnes, J. C., Day, N. C., Bradley, P., Reed, J. Z., and Tropsha, A. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species Chem. Res. Toxicol. 23, 171-183
46. Unger, M. and Frank, A. (2004) Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction Rapid. Commun. Mass. Spectrom. 18, 2273-2281 (Pubitemid 39297365)
47. Mathews, J. M., Etheridge, A. S., and Black, S. R. (2002) Inhibition of human cytochrome P450 activities by kava extract and kavalactones Drug Metab. Dispos. 30, 1153-1157 (Pubitemid 35265819)
48. Mathews, J. M., Etheridge, A. S., Valentine, J. L., Black, S. R., Coleman, D. P., Patel, P., So, J., and Burka, L. T. (2005) Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro Drug Metab. Dispos. 33, 1555-1563 (Pubitemid 41324005)
49. Zou, L., Harkey, M. R., and Henderson, G. L. (2005) Synthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion Planta Med. 71, 142-146 (Pubitemid 40363557)
50. Coleman, M. D. (2005) Human Drug Metabolism an Introduction, Wiley, Chichester, U.K.
51. Zou, L., Harkey, M. R., and Henderson, G. L. (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity Life Sci. 71, 1579-1589 (Pubitemid 34808718)
52. Dierks, E. A., Stams, K. R., Lim, H.-K., Cornelius, G., Zhang, H., and Ball, S. E. (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry Drug Metab. Dispos. 29, 23-29 (Pubitemid 32041675)
53. Johnson, B. M., Qiu, S. X., Zhang, S., Zhang, F., Burdette, J. E., Yu, L., Bolton, J. L., and van Breemen, R. B. (2003) Identification of novel electrophilic metabolites of Piper methysticum Forst (Kava) Chem. Res. Toxicol. 16, 733-740 (Pubitemid 36736604)
54. Hodgson, E. and Levi, P. E. (1998) Interactions of Piperonyl Butoxide with Cytochrome P450, in Piperonyl Butoxide: The Insecticide Synergist (Jones, D. G., Ed.) pp 41-54, Academic Press, San Diego, CA.
55. Ortiz de Montellano, P. R. and Correia, M. A. (2005) Inhibition of Cytochrome P450 Enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) Kluwer Academic/Plenum Publishers, New York.
56. Weiss, J., Sauer, A., Frank, A., and Unger, M. (2005) Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro Drug Metab. Dispos. 33, 1580-1583 (Pubitemid 41539951)
57. Zhou, S., Lim, L. Y., and Chowbay, B. (2004) Herbal modulation of P-glycoprotein Drug Metab. Rev. 36, 57-104 (Pubitemid 38387835)
58. Guo, L., Li, Q., Xia, Q., Dial, S., Chan, P. C., and Fu, P. (2009) Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract Food Chem. Toxicol. 47, 433-442
59. Yamazaki, Y., Hashida, H., Arita, A., Hamaguchi, K., and Shimura, F. (2008) High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats Food Chem. Toxicol. 46, 3732-3738
60. Lim, S. T., Dragull, K., Tang, C. S., Bittenbender, H. C., Efird, J. T., and Nerurkar, P. V. (2007) Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats Toxicol. Sci. 97, 214-221 (Pubitemid 47072170)
61. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Khan, I. A., and Shah, A. (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes Clin. Pharmacol. Ther. 77, 415-426 (Pubitemid 40719269)
62. Ernst, E. (2007) A re-evaluation of kava (Piper methysticum) Br. J. Clin. Pharmacol. 64, 415-417 (Pubitemid 47404312)
63. Wanwimolruk, S., Bhawan, S., Coville, P. F., and Chalcroft, S. C. (1998) Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations Eur. J. Clin. Pharmacol. 54, 431-435 (Pubitemid 28396318)
64. Ingelman-Sundberg, M. (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J. 5, 6-13 (Pubitemid 40220611)
65. Russmann, S., Barguil, Y., Cabalion, P., Kritsanida, M., Duhet, D., and Lauterburg, B. H. (2003) Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia Eur. J. Gastroenterol. Hepatol. 15, 1033-1036 (Pubitemid 37094305)
66. Kaneko, A., Kaneko, O., Taleo, G., Bjorkman, A., and Kobayakawa, T. (1997) High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu Lancet 349, 921-922 (Pubitemid 27139824)
67. Kaneko, A., Lum, J. K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., Kobayakawa, T., and Bjorkman, A. (1999) High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands Pharmacogenetics 9, 581-590
68. Nerurkar, P. V., Dragull, K., and Tang, C. S. (2004) In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones Toxicol. Sci. 79, 106-111 (Pubitemid 38660254)
69. Lüde, S., Török, M., Dieterle, S., Jäggi, R., Büter, K. B., and Krähenbühl, S. (2008) Hepatocellular toxicity of kava leaf and root extracts Phytomedicine 15, 120-131 (Pubitemid 350297905)
70. Lechtenberg, M., Quandt, B., Schmidt, M., and Nahrstedt, A. (2008) Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Pharmazie 63, 71-74 (Pubitemid 351187597)
71. Sabzevari, O., Galati, G., Moridani, M. Y., Siraki, A., and OBrien, P. J. (2004) Molecular cytotoxic mechanisms of anticancer hydroxychalcones Chem.-Biol. Interact. 148, 57-67 (Pubitemid 38824661)
72. Wu, D., Nair, M. G., and DeWitt, D. L. (2001) Novel compounds from Piper methysticum Forst (Kava Kava) roots and their effect on cyclooxygenase enzyme J. Agric. Food. Chem. 50, 701-705 (Pubitemid 34163609)
73. Knight, E. V., Kimball, J. P., Keenan, C. M., Smith, I. L., Wong, F. A., Barrett, D. S., Dempster, A. M., Lieuallen, W. G., Panigrahi, D., Powers, W. J., and Szot, R. J. (1996) Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs Fundam. Appl. Toxicol. 33, 38-48
74. Fu, P. P., Xia, Q. S., Guo, L., Yu, H. T., and Chan, P. C. (2008) Toxicity of kava kava J. Environ. Sci. Health. C 26, 89-112 (Pubitemid 351347047)
75. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., ODonnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6, 161-225 (Pubitemid 40753853)
76. Kalgutkar, A. S. and Didiuk, M. T. (2009) Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem. Biodiversity 6, 2115-2137
77. Xuan, T. D., Fukuta, M., Wei, A. C., Elzaawely, A. A., Khanh, T. D., and Tawata, S. (2008) Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots J. Nat. Med. 62, 188-194 (Pubitemid 351365814)
78. Schmidt, M. (2003) Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory J. Altern. Complement. Med. 9, 183-187; author reply 187-188
79. Naisbitt, D. J. (2004) Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests Toxicology 194, 179-196 (Pubitemid 37542452)
80. Sohlenius-Sternbeck, A. K. and Schmidt, S. (2005) Impaired glutathione-conjugating capacity by cryopreserved human and rat hepatocytes Xenobiotica 35, 727-736 (Pubitemid 41441522)
81. Knowles, S. R., Uetrecht, J., and Shear, N. H. (2000) Idiosyncratic drug reactions: the reactive metabolite syndromes Lancet 356, 1587-1591
82. Park, B. K., Kitteringham, N. R., Powell, H., and Pirmohamed, M. (2000) Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity Toxicology 153, 39-60
83. Teschke, R., Sarris, J., and Lebot, V. (2011) Kava hepatotoxicity solution: A six-point plan for new kava standardization Phytomedicine 18, 96-103
84. Sarris, J., Teschke, R., Stough, C., Scholey, A., and Schweitzer, I. (2011) Re-introduction of kava (Piper methysticum) to the EU: Is there a way forward? Planta Med. 77, 107-110
85. Teschke, R., Sarris, J., Glass, X., and Schulze, J. (2011) Kava, the anxiolytic herb: back to basics to prevent livcer injury? Br. J. Clin. Pharmacol. 71, 445-448